Vertex Pharmaceuticals (VRTX) Total Non-Current Liabilities (2009 - 2026)

Vertex Pharmaceuticals' Total Non-Current Liabilities history runs 18 years deep, the most recent figure standing at $5.9 billion for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 8.0% year-over-year to $5.9 billion in Q1 2026; TTM through Mar 2026 was $5.9 billion, a 8.0% increase from a year earlier, with the FY2025 full-year figure at $5.7 billion, up 11.72% from the prior year.
• Total Non-Current Liabilities grew to $5.9 billion in Q1 2026 per VRTX's latest filing, from $5.7 billion in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $6.3 billion in Q3 2025 and bottomed at $3.2 billion in Q1 2022.
• The 5-year median for Total Non-Current Liabilities is $4.5 billion (2024), against an average of $4.7 billion.
• Across the five-year window, Total Non-Current Liabilities gained 6.71% in 2022 and soared 30.66% in 2024, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $3.6 billion in 2022, then climbed by 20.26% to $4.3 billion in 2023, then climbed by 19.59% to $5.1 billion in 2024, then advanced by 11.72% to $5.7 billion in 2025, then climbed by 2.79% to $5.9 billion in 2026.
• Per Business Quant, the three latest VRTX Total Non-Current Liabilities figures stand at $5.9 billion (Q1 2026), $5.7 billion (Q4 2025), and $6.3 billion (Q3 2025).